Reduced expression of the metastasis suppressor gene KAI1 in advanced colon cancer and its metastases

Maurer, Christoph A.; Graber, H.U.; Frieß, Helmut; Beyermann, Beate; Willi, Doris; Netzer, Peter; Zimmermann, Arthur; ]chler, Markus W. B[uuml

doi:10.1067/msy.2099.100381

Cited by 8 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although anti-CD82 antibodies come from 10 companies, the subjects of 5 countries are involved in our study, and different statistical methods are employed, CD82 expression and its correlation with clinicopathological parameters are comparatively consistent, indicating that these antibodies mainly recognize CD82 protein and its expression is independent of population or not determined by statistics. It was noted that CD82 mRNA overexpression was observed in gastric cancer according to bioinformatics analysis, in agreement with the finding about thyroid papillary carcinoma [56] and colorectal cancer [57]. The discrepancy might be due The bias was analyzed about risk degrees of CD82 expression in gastric mucosa (A) for gastric carcinogenesis.…”

Section: Discussionsupporting

confidence: 70%

The roles of CD82 expression in gastric cancer: a meta and bioinformatics analysis

Zheng¹,

Gong²

2017

Oncotarget

View full text Add to dashboard Cite

CD82 encodes a transmembrane glycoprotein of tetraspanins family, and functions as a tumor metastasis suppressor. We performed a systematic meta and bioinformatics analysis through multiple online databases up to March 14, 2017. We¬ found down-regulated CD82 expression in gastric cancer, compared with normal mucosa (p < 0.05). CD82 expression was negatively with depth of invasion, lymph node and distant metastasis, TNM staging and dedifferentiation of gastric cancer (p < 0.05). A positive association between CD82 expression and favorable overall survival was found in patients with gastric cancer (p < 0.005). According to bioinformatics analysis, CD82 mRNA expression was higher in gastric cancer than normal tissues (p < 0.05). According to Kaplan-Meier plotter and TCGA database, we found that a higher CD82 expression was positively correlated with overall or progression-free survival rates of all cancer patients, even stratified by aggressive parameters or as an independent factor (p < 0.05). These findings indicated that CD82 expression might be employed as a potential marker to indicate gastric carcinogenesis and subsequent progression, even favorable prognosis.

show abstract

Section: Discussionsupporting

confidence: 70%

The roles of CD82 expression in gastric cancer: a meta and bioinformatics analysis

Zheng¹,

Gong²

2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…However, in prostate cell lines, induction of p53 with DNA damaging agents did not increase KAI1 expression. So, it remains questionable whether KAI1 is the primary target of the tumour suppressor protein p53 (Adachi et al 1996;Mashimoto et al 1998;Maurer et al 1999;Jackson & Puisieux 2000;Shinohara et al 2001).…”

Section: Kiss1mentioning

confidence: 99%

Reduced protein expression of metastasis‐related genes (nm23, KISS1, KAI1 and p53) in lymph node and liver metastases of gastric cancer

Chen

et al. 2007

Int J Experimental Path

View full text Add to dashboard Cite

show abstract

“…Our results showing the elevated expression of claudin-1, −3 and −4, EpCAM, E-cadherin in colon cancer were consistent with earlier studies [11,22,23] . Previously it was shown that decreased expressions of CD9 [24] and CD82 were vital for colon cancer metastasis, and particularly reduced expression of CD82 was related with metastatic colon [25] and gastric cancer [26]. Here, we have also identified expression changes in seven PKC isoforms in both normal colon cells and colon cancer cells.…”

Section: Discussionmentioning

confidence: 56%

Protein kinase C Inhibitors selectively modulate dynamics of cell adhesion molecules and cell death in human colon cancer cells

Dükel

Tavsan

Erdogan

et al. 2018

Cell Adhesion & Migration

View full text Add to dashboard Cite

During development of colon cancer, Protein Kinase Cs (PKCs) are involved in regulation of many genes controlling several cellular mechanisms. Here, we examined the changes in cell adhesion molecules and PKCs for colorectal cancer progression. We identified that PKCs affected expression of EpCAM, claudins, tetraspanins. Treatment with low concentrations of PKC inhibitors resulted in decreased cell viability. In addition, immunoblotting and qRT-PCR analysis showed that apoptosis was inhibited while autophagy was induced by PKC inhibition in colon cancer cells. Furthermore, we observed decreased levels of intracellular Reactive Oxygen Species (ROS), lipid peroxidation and protein carbonyl, confirming the ROS-induced apoptosis. Taken together, our results reveal that PKC signalling modulates not only cell adhesion dynamics but also cell death-related mechanisms.

show abstract

Reduced expression of the metastasis suppressor gene KAI1 in advanced colon cancer and its metastases

Abstract: These data demonstrate that the KAI1 mRNA expression and the KAI1 protein level increase in an earlier tumor stage of colorectal cancer, decrease in advanced stages, and are lost in metastases. The loss of KAI1 might favor the ability of colorectal cancer cells to metastasize.

Cited by 8 publications

References 0 publications

The roles of CD82 expression in gastric cancer: a meta and bioinformatics analysis

The roles of CD82 expression in gastric cancer: a meta and bioinformatics analysis

Reduced protein expression of metastasis‐related genes (nm23, KISS1, KAI1 and p53) in lymph node and liver metastases of gastric cancer

Protein kinase C Inhibitors selectively modulate dynamics of cell adhesion molecules and cell death in human colon cancer cells

Contact Info

Product

Resources

About